Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke
Group Managing Director, Kate Quirke
Source: Alcidion Group
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Alcidion Group (ALC) has signed two contracts with Murrumbidgee Local Health District (LHD) to keep using Alcidion’s Miya Precision platform and Miya MEMRe
  • The total combined contract value is $686,000 and runs for a period of 12 months
  • Once deployed, a COVID-19 monitoring capability will be integrated with Miya Precision to assess COVID-19 positive and at-risk patients
  • Additionally, Miya MEMRe will be rolled out to up to 200 clinicians, which is set to reduce the risk of infection from shared devices
  • Company shares are up 3.33 per cent and are trading for 15.5 cents each

Alcidion Group (ALC) has signed two contracts with Murrumbidgee Local Health District (LHD) for continued use of Alcidion’s Miya Precision platform and Miya MEMRe.

In April, Murrumbidgee LHD chose to use Miya Precision for 12 months, starting from January 1. The two contracts have a combined value of $686,000 and are intended to be used at the Wagga Wagga Base Hospital.

Miya Precision provides artificial intelligence-based predictive analysis, clinical support and mobile alerts in an easy-to-use dashboard.

Once deployed, a COVID-19 monitoring capability will be incorporated into Miya Precision to monitor COVID-19 positive and at-risk patients both in-hospital and remotely.

Miya MEMRe will also be rolled out to up to 200 clinicians, which is set to reduce the risk of infection from using shared devices.

Miya MEMRe is a mobile EMR solution which provides real-time and easy access to critical test results and risk indicators to improve clinical decision-making.

“We are delighted that Murrumbidgee LHD has elected to use Miya Precision and MEMRe,” Alcidion Managing Director Kate Quirke said.

“Furthermore, we are pleased to work with the team at Murrumbidgee LHD to further develop the COVID-19 monitoring solution to meet their needs as they utilise vital resources to manage the impact of this ongoing situation,” Kate added.

Company shares are up 3.33 per cent and are trading for 15.5 cents each at 1:01 pm AEST.

ALC by the numbers
More From The Market Herald

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…